background : transarterial chemoembolization is the preferred treatment for unresectable, intermediate-stage hepatocellular carcinoma. survival after transarterial chemoembolization can be highly variable. the purpose of this study is to identify the factors that predict overall survival of patients with unresectable hepatocellular carcinoma who undergo transarterial chemoembolization as the in...

OBJECTIVE Transarterial chemoembolization is the treatment of choice for intermediate-stage hepatocellular carcinoma. However, there are no clear data supporting transarterial chemoembolization vs . transarterial embolization or regarding the best chemotherapeutic agent, which may suggest a preponderant role of ischemia over chemotherapeutic action. This study sought to evaluate the radiologica...

following failure of systemic chemotherapy, transarterial chemoembolization (tace) is an available method to control unresectable liver metastases from colorectal carcinoma (crc). the aim of present study was to evaluate the efficacy of chemoembolization for inoperable metastatic liver lesions from crc. forty-five crc patients with liver metastases resistant to systemic chemotherapy were enroll...

♦Corresponding Author: Muhammed Mubarak, MD Histopathology Department, Sindh Institute of Urology and Transplantation, Karachi-74200, Pakistan Tel: +9221 99215752 Fax: +9221 32726165 Email: [email protected] Abstract Background: Transarterial chemoembolization is the preferred treatment for unresectable, intermediate-stage hepatocellular carcinoma. Survival after transarterial chemoemboli...

Introduction. Transarterial chemoembolization is the first-line treatment in unresectable hepatocellular carcinoma. There is no standard treatment after transarterial chemoembolization failure. We report the case of a patient with advanced hepatocellular carcinoma who showed a complete response and a long cancer control with hypofractionated stereotactic radiotherapy after transarterial chemoem...

patients and methods this was a retrospective study including 207 consecutive patients who were enrolled using computerized hepatocellular carcinoma database consisting of 105 patients who underwent combined tace with rfa, and 102 patients who underwent tace alone with long-term follow-up. results the complete remission rate was meaningfully higher in the combination group (97.1%, 102/105) than...

We report two cases of liver metastases from colorectal and anal cancers after the failure systemic chemotherapies that were successfully treated with a combination therapy transarterial chemoembolization using irinotecan-loaded drug-eluting beads hepatic arterial infusion chemotherapy. In both cases, chemotherapy was performed as maintenance beads. Irinotecan at dose 120 mg loaded on drug deli...

PURPOSE To review the available evidence of chemoembolization for unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS Computerized bibliographic searches with MEDLINE and CANCERLIT databases from 1980 through 2000 were supplemented with manual searches, with the keywords "hepatocellular carcinoma," "liver cell carcinoma," "randomized controlled trial [RCT]," and "chemoembolizat...

Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment op...

BACKGROUND According to Barcelona Clinic Liver Cancer classification transarterial chemoembolization is indicated in patients with Hepatocellular Carcinoma in the intermediate stage. Drug-eluting microspheres can absorb and release the chemotherapeutic agent slowly for 14 days after its intra-arterial administration. This type of transarterial chemoembolization approach appears to provide at le...